Early detection is one of the most important factors influencing the outcome of many human diseases.

Several pathological processes begin at the molecular and cellular levels long before clinical symptoms become apparent.

Traditional diagnostic approaches frequently depend on clinical symptoms, imaging, physiological measurements, and conventional laboratory tests.

Although these methods remain essential, they may not always detect disease during its earliest stages.

Molecular biomarkers provide an opportunity to identify biological changes associated with disease development.

A biomarker can be defined as a measurable biological characteristic that provides information about a physiological or pathological process or response to an intervention.

Molecular biomarkers can include proteins, nucleic acids, metabolites, lipids, epigenetic alterations, and other measurable molecular changes.

The increasing availability of high-throughput technologies has accelerated biomarker discovery.

Genomic sequencing, transcriptomic profiling, proteomic analysis, metabolomics, and advanced molecular imaging have generated large amounts of biological information that can be used to identify disease-associated signatures.

Molecular biomarkers have applications across multiple stages of disease management.

They can assist with early detection, diagnosis, disease classification, prognosis, monitoring of treatment response, and prediction of recurrence.

However, discovery of a statistically associated biomarker does not automatically establish its clinical usefulness.

A biomarker must undergo analytical validation, clinical validation, and assessment of clinical utility before widespread implementation.

This review examines the role of molecular biomarkers in early detection and prognosis of human diseases and discusses the challenges involved in translating biomarker discoveries into clinical practice.

Characteristics of an Ideal Molecular Biomarker

An effective molecular biomarker should possess several characteristics.

Ideally, it should be highly specific for the disease process and sufficiently sensitive to detect disease at an early stage.

It should also be reproducible, stable, measurable using standardized techniques, and relatively easy to obtain.

No single biomarker necessarily fulfills all these requirements.

Consequently, combinations of multiple biomarkers are increasingly investigated.

Major Classes of Molecular Biomarkers

Molecular biomarkers can be classified according to their biological composition.

The major categories include:

• Protein biomarkers;
• DNA biomarkers;
• RNA biomarkers;
• MicroRNAs;
• Epigenetic biomarkers;
• Metabolic biomarkers;
• Lipid biomarkers;
• Extracellular vesicles;
• Circulating tumor DNA; and
• Cell-based biomarkers.

Each category provides different information about disease biology.

Protein Biomarkers

Proteins are among the most extensively studied biomarker classes.

Changes in protein concentration, structure, modification, or activity can reflect pathological processes.

Proteins can be measured in blood, urine, cerebrospinal fluid, tissue, and other biological samples.

Examples of clinically important protein biomarkers include cardiac troponins for myocardial injury and prostate-specific antigen for prostate-related conditions.

However, protein biomarkers can be influenced by age, sex, inflammation, medication, renal function, and other physiological factors.

Therefore, interpretation often requires integration with clinical information.

DNA Biomarkers

DNA biomarkers provide information about genetic alterations associated with disease.

These may include:

• Point mutations;
• Insertions and deletions;
• Copy-number alterations;
• Chromosomal rearrangements;
• Microsatellite instability; and
• Germline genetic variants.

DNA biomarkers are particularly important in oncology and inherited diseases.

Genetic alterations can also provide prognostic information and help identify patients who may benefit from specific therapies.

Circulating Cell-Free DNA

Cell-free DNA consists of DNA fragments present in biological fluids, particularly blood plasma.

A proportion of circulating DNA can originate from diseased or damaged cells.

In cancer patients, tumor-derived circulating DNA may contain molecular alterations characteristic of the tumor.

This has led to the development of liquid biopsy approaches.

Liquid biopsy offers a minimally invasive method for detecting molecular abnormalities without requiring repeated tissue biopsies.

Circulating Tumor DNA

Circulating tumor DNA represents a fraction of cell-free DNA released by malignant cells.

Its analysis may provide information about tumor genetics.

Potential applications include:

• Early cancer detection;
• Molecular classification;
• Treatment selection;
• Detection of minimal residual disease;
• Monitoring treatment response; and
• Detection of molecular recurrence.

One major challenge is that the amount of tumor-derived DNA can be extremely low, particularly in early-stage disease.

Highly sensitive analytical technologies are therefore required.

RNA Biomarkers

RNA molecules provide information about gene expression and cellular activity.

Messenger RNA profiles can reveal changes in transcription associated with disease.

Long non-coding RNAs and other regulatory RNA molecules may also serve as biomarkers.

RNA signatures can potentially distinguish between healthy and diseased tissues and may provide prognostic information.

However, RNA can be relatively unstable in biological samples, creating challenges for sample handling and analysis.

MicroRNAs as Biomarkers

MicroRNAs are small non-coding RNA molecules that regulate gene expression.

They influence multiple biological processes, including proliferation, differentiation, apoptosis, metabolism, and inflammation.

Abnormal microRNA expression has been associated with numerous diseases.

Because microRNAs can circulate in blood and other body fluids and may be relatively stable when associated with proteins or extracellular vesicles, they have attracted substantial interest as non-invasive biomarkers.

Epigenetic Biomarkers

Epigenetic changes regulate gene activity without altering the underlying DNA sequence.

Important epigenetic mechanisms include:

• DNA methylation;
• Histone modification;
• Chromatin remodeling; and
• Non-coding RNA regulation.

Disease-associated methylation patterns can sometimes be detected in circulating DNA.

These molecular changes may provide information about disease development and prognosis.

Metabolic Biomarkers

Metabolites reflect the biochemical state of cells and tissues.

Metabolic alterations can occur early during disease development.

Metabolomics technologies can measure large numbers of metabolites simultaneously.

Potential metabolic biomarkers include changes in:

• Amino acids;
• Lipids;
• Carbohydrates;
• Organic acids;
• Nucleotides; and
• Energy metabolites.

Metabolic signatures have been investigated in cancer, diabetes, cardiovascular disease, neurological disorders, and liver disease.

Extracellular Vesicles

Extracellular vesicles are membrane-bound particles released by cells.

They can contain proteins, lipids, DNA, messenger RNA, microRNAs, and other molecules.

Because extracellular vesicles can transport biological information between cells, they are increasingly investigated as potential disease biomarkers.

Their molecular contents may reflect the physiological state of the cells from which they originate.

Biomarkers in Cancer

Cancer is one of the most important areas of molecular biomarker research.

Tumor development involves genetic, epigenetic, transcriptomic, proteomic, and metabolic alterations.

These changes can produce molecular signatures that distinguish malignant cells from normal cells.

Biomarkers can support several aspects of cancer management.

Molecular Biomarkers in Cardiovascular Disease

Cardiovascular disease remains a major cause of morbidity and mortality worldwide.

Molecular biomarkers can assist in identifying tissue injury and evaluating disease severity.

Cardiac troponins are established biomarkers of myocardial injury.

Other molecular markers, including natriuretic peptides, inflammatory mediators, microRNAs, and metabolic signatures, have been investigated for cardiovascular risk assessment and prognosis.

Combining molecular biomarkers with clinical parameters may improve risk stratification.

Biomarkers in Neurodegenerative Disorders

Neurodegenerative diseases can develop gradually over many years.

By the time significant neurological symptoms appear, substantial neuronal damage may already have occurred.

This creates a strong need for early molecular biomarkers.

Potential biomarkers include:

• Amyloid-related proteins;
• Tau proteins;
• Neurofilament proteins;
• MicroRNAs;
• Inflammatory molecules; and
• Metabolic signatures.

Cerebrospinal fluid and blood-based biomarkers are being extensively investigated.

The development of reliable blood-based biomarkers may significantly improve accessibility of neurological disease assessment.

Biomarkers in Metabolic Diseases

Metabolic disorders involve complex changes in energy metabolism, inflammation, and hormonal regulation.

Diabetes, obesity, and metabolic syndrome can produce changes in proteins, metabolites, lipids, and nucleic acids.

Metabolic biomarkers may help identify individuals at increased risk before severe disease develops.

Combining metabolic profiles with genetic and clinical information may improve prediction of disease progression.

Biomarkers in Liver Disease

Liver diseases often develop silently during early stages.

Molecular biomarkers may help identify hepatocellular injury, fibrosis, inflammation, and malignant transformation.

Potential biomarker classes include circulating proteins, microRNAs, cell-free DNA, metabolites, and extracellular vesicles.

Combining multiple molecular markers may improve discrimination between different stages of liver disease.

Biomarkers in Kidney Disease

Traditional indicators of kidney function may not detect renal injury immediately.

Molecular biomarkers have therefore been investigated for earlier detection of kidney damage.

Potential biomarkers include proteins, inflammatory mediators, urinary nucleic acids, metabolites, and extracellular vesicles.

Urine represents an attractive sample source because it can be collected non-invasively.

Biomarkers in Inflammatory Diseases

Chronic inflammatory diseases involve persistent activation of immune and cellular signaling pathways.

Molecular biomarkers can provide information about inflammatory activity.

Potential markers include cytokines, chemokines, acute-phase proteins, microRNAs, and immune-cell-associated molecules.

Biomarker panels may help distinguish active disease from remission and may assist in monitoring treatment response.

Liquid Biopsy

Liquid biopsy refers to molecular analysis of disease-associated material obtained from body fluids.

Blood is the most commonly investigated source, but other fluids can also provide valuable molecular information.

Liquid biopsy can analyze:

• Cell-free DNA;
• Circulating tumor DNA;
• Circulating RNA;
• MicroRNAs;
• Extracellular vesicles; and
• Circulating cells.

Its minimally invasive nature makes it particularly attractive for repeated disease monitoring.

Multi-Omics Biomarker Discovery

Modern biomarker research increasingly integrates multiple molecular data types.

Integration of these datasets may produce more accurate disease signatures than individual biomarkers.

Artificial Intelligence and Biomarker Discovery

Large molecular datasets can be difficult to interpret using conventional statistical methods.

Machine-learning and artificial-intelligence approaches can identify complex molecular patterns.

These methods may assist in:

• Biomarker discovery;
• Disease classification;
• Risk prediction;
• Patient stratification;
• Prognostic modeling; and
• Prediction of treatment response.

However, computational models require independent validation to avoid overfitting and ensure reproducibility

Review Design

The present article was prepared as a narrative review of molecular biomarkers used or investigated for early detection and prognosis of human diseases.

Literature Search

Relevant scientific literature was considered from biomedical databases and peer-reviewed journals.

Search terms included combinations of:

“molecular biomarkers,” “early detection,” “prognostic biomarkers,” “diagnostic biomarkers,” “liquid biopsy,” “cell-free DNA,” “circulating tumor DNA,” “microRNA,” “proteomics,” “metabolomics,” “epigenetic biomarkers,” “extracellular vesicles,” “cancer biomarkers,” “cardiovascular biomarkers,” “neurodegenerative biomarkers,” and “precision medicine.”

Inclusion Criteria

Publications were considered relevant when they examined:

• Molecular biomarkers for human disease;
• Early disease detection;
• Prognostic biomarkers;
• Disease-associated molecular signatures;
• Liquid biopsy technologies;
• Multi-omics biomarker discovery; or
• Clinical translation of molecular biomarkers.

Exclusion Criteria

Studies without substantial relevance to molecular biomarkers or human disease detection and prognosis were excluded from the primary synthesis.

Data Synthesis

The available evidence was organized according to biomarker type, disease application, analytical technology, diagnostic value, prognostic potential, and clinical limitations.

Results

The reviewed evidence demonstrates that molecular biomarkers have considerable potential for improving early disease detection and prognostic assessment.

Major findings are summarized below.

Overall, the evidence suggests that biomarker panels and multi-parameter models may provide greater diagnostic and prognostic performance than individual markers.

Prognostic Biomarkers

Prognostic biomarkers provide information about the likely course of disease.

They may indicate:

• Disease progression;
• Risk of recurrence;
• Probability of complications;
• Survival probability; or
• Response-independent disease severity.

In oncology, molecular prognostic markers can help distinguish patients with aggressive disease from those with more favorable disease characteristics.

Similar approaches are being developed for cardiovascular, neurological, metabolic, and inflammatory disorders.

Predictive Versus Prognostic Biomarkers

The concepts of prognostic and predictive biomarkers should be distinguished.

A prognostic biomarker provides information about disease outcome independent of a specific treatment.

A predictive biomarker provides information about the likelihood that a patient will respond to a particular treatment.

Understanding this distinction is essential for clinical biomarker development.

Biomarker Panels

A single biomarker may lack sufficient sensitivity or specificity.

Combining several molecular markers can improve diagnostic performance.

For example, a biomarker panel may combine:

• Protein concentrations;
• DNA alterations;
• microRNA expression;
• Metabolic features; and
• Clinical characteristics.

Multimarker approaches can capture different aspects of disease biology.

However, larger panels may increase analytical complexity and cost.

Early Detection and Disease Prevention

The greatest potential benefit of molecular biomarkers may be their ability to identify disease before irreversible tissue damage occurs.

Early detection can create opportunities for:

• Earlier treatment;
• Improved monitoring;
• Prevention of complications;
• Patient risk stratification; and
• More effective therapeutic intervention.

However, early detection biomarkers must demonstrate that their use improves clinical outcomes rather than simply detecting molecular abnormalities.

Challenges in Biomarker Development

Despite substantial progress, several barriers limit clinical implementation.

Biological Variability

Biomarker concentrations can vary according to age, sex, genetics, diet, medication, inflammation, and other physiological factors.

Analytical Variability

Different laboratories may use different instruments, reagents, and analytical procedures.

This can produce inconsistent results.

Limited Specificity

Some biomarkers are associated with multiple diseases.

A marker elevated in cancer may also increase during inflammation or tissue injury.

Early Disease Sensitivity

The molecular signal may be extremely small during early disease.

Highly sensitive technologies are therefore required.

Clinical Validation

Many biomarkers demonstrate promising results in research studies but lack validation in large independent populations.

Clinical Translation

Successful clinical translation requires several stages.

The discovery stage identifies candidate biomarkers.

Analytical validation determines whether the assay accurately and reproducibly measures the biomarker.

Clinical validation evaluates its association with disease.

Clinical utility determines whether using the biomarker actually improves patient management or outcomes.

Finally, regulatory and implementation considerations must be addressed.

This process is essential for separating promising biomarkers from clinically useful biomarkers.

Molecular biomarkers have transformed biomedical research by providing direct insight into disease-associated biological changes.

Traditional clinical indicators often reflect downstream consequences of disease.

Molecular biomarkers can potentially identify upstream biological alterations.

This distinction is particularly important for diseases with long asymptomatic periods.

Cancer provides one of the strongest examples.

Tumor cells accumulate genetic and epigenetic alterations during malignant transformation.

Some of these alterations can enter circulation and become detectable through liquid biopsy.

However, early-stage tumors may release extremely small quantities of tumor-derived molecules.

Consequently, sensitivity remains a major challenge.

The development of highly sensitive sequencing and molecular detection technologies has improved the ability to identify rare molecular signals.

MicroRNAs represent another promising biomarker class.

Their involvement in multiple regulatory pathways means that changes in their expression can reflect disease-associated biological processes.

However, the same microRNA can participate in different diseases, limiting disease specificity.

This suggests that microRNA panels may be more useful than individual microRNAs.

Proteomic and metabolomic biomarkers provide complementary information.

Proteins can reflect inflammatory, structural, and signaling changes, while metabolites provide information about functional metabolic states.

Integration of these molecular layers may therefore improve disease characterization.

Multi-omics approaches are particularly attractive because human diseases are rarely caused by changes in a single molecular pathway.

Instead, disease usually involves interactions between genetic, epigenetic, transcriptional, protein, metabolic, and environmental factors.

Artificial intelligence may facilitate analysis of these complex datasets.

Machine-learning algorithms can identify combinations of molecular features that are difficult to recognize using conventional approaches.

Nevertheless, computational performance must be evaluated using independent datasets.

A model that performs well in its development population may perform poorly in a different population because of differences in genetics, environment, sample collection, or disease prevalence.

Another important consideration is clinical utility.

A biomarker may demonstrate excellent statistical performance but provide little practical benefit if it does not change clinical management.

Therefore, future research should focus not only on discovering biomarkers but also on determining how they can improve patient outcomes.

Future Perspectives

Future biomarker research is expected to move increasingly toward integrated molecular signatures.

Combining genomics, transcriptomics, proteomics, metabolomics, and epigenomics may provide a more comprehensive representation of disease biology.

Single-cell technologies may further improve biomarker discovery by identifying molecular changes within specific cell populations.

Liquid biopsy is also likely to remain an important research area because it enables minimally invasive sampling.

Advances in sequencing technology may increase sensitivity sufficiently to detect very low levels of disease-associated molecules.

Artificial intelligence may facilitate interpretation of complex biomarker profiles and improve individualized risk prediction.

Another important direction is development of standardized protocols for biomarker collection, processing, analysis, and reporting.

Standardization will be essential for reproducibility and clinical adoption.

Future studies should also include diverse populations to ensure that biomarker performance is not restricted to a particular demographic or geographic group.

Molecular biomarkers provide valuable information about biological processes associated with disease development, progression, and treatment response.

Protein markers, DNA alterations, circulating nucleic acids, microRNAs, epigenetic signatures, metabolites, extracellular vesicles, and multi-omics profiles all represent important areas of biomarker research.

Their potential applications include early disease detection, diagnosis, prognostic assessment, treatment selection, treatment monitoring, and recurrence detection.

Cancer has been a major focus of molecular biomarker research, particularly through liquid biopsy and circulating tumor DNA technologies.

However, molecular biomarkers are also increasingly investigated in cardiovascular, neurological, metabolic, hepatic, renal, and inflammatory diseases.

The major challenges include biological variability, limited specificity, analytical differences, insufficient early-stage sensitivity, and lack of large-scale clinical validation.

Future progress will depend on combining multiple biomarkers with advanced sequencing, multi-omics analysis, artificial intelligence, and standardized clinical validation.

Ultimately, the successful translation of molecular biomarkers into routine clinical practice may enable earlier diagnosis, more accurate prognostic assessment, and increasingly personalized approaches to human disease management.

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology & Therapeutics. 2001;69:89–95.
2. Mayeux R. Biomarkers: potential uses and limitations. NeuroRx. 2004;1:182–188.
3. Califf RM. Biomarker definitions and their applications. Experimental Biology and Medicine. 2018;243:213–221.
4. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–930.
5. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nature Reviews Genetics. 2019;20:71–88.
6. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer. 2017;17:223–238.
7. Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nature Reviews Clinical Oncology. 2021;18:297–312.
8. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free DNA in cancer. Nature Reviews Clinical Oncology. 2011;8:145–156.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.
10. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–838.
11. Esteller M. Epigenetics in cancer. New England Journal of Medicine. 2008;358:1148–1159.
12. Armitage EG, Barbas C. Metabolomics and cancer biomarker discovery: the challenges and prospects. Journal of Pharmaceutical and Biomedical Analysis. 2014;87:1–12.
13. Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer. Nature Reviews Clinical Oncology. 2011;8:142–150.
14. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:eaau6977.
15. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018. Journal of Extracellular Vesicles. 2018;7:1535750.
16. Mayeux R. Early diagnosis of neurodegenerative diseases: methodological and clinical considerations. Alzheimer's & Dementia. 2008;4:S91–S98.
17. Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and future perspectives. Journal of Internal Medicine. 2018;284:643–663.
18. de Lemos JA, Morrow DA. Cardiac biomarkers in acute coronary syndromes. Circulation. 2013;127:237–248.
19. Daniels LB, Maisel AS. Natriuretic peptides. Journal of the American College of Cardiology. 2007;50:2357–2368.
20. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature Biotechnology. 2006;24:971–983.
21. Diamandis EP. Biomarkers in cancer: can we improve on nature? Clinical Chemistry. 2007;53:1587–1589.
22. Sawyers CL. The cancer biomarker problem. Nature. 2008;452:548–552.
23. Poste G. Bring on the biomarkers. Nature. 2011;469:156–157.
24. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113:2335–2362.
25. McDermott JE, Wang J, Mitchell H, et al. Challenges in biomarker discovery: combining computational and experimental approaches. Expert Review of Proteomics. 2013;10:499–510.